论文部分内容阅读
目的:探讨分析派罗欣联合利巴韦林治疗慢性丙肝的临床效果。方法:选取我院2010年5月-2013年6月收治的62例慢性丙肝患者为研究对象,将其随机分成A组与B组,A组30例患者给予干扰素联合利巴韦林进行治疗,B组32例患者给予派罗欣联合利巴韦林进行治疗,观察两组治疗效果与不良反应情况。结果:A组患者终点应答率为53.3%,B组患者为87.5%,B组患者应答率明显高于A组,差异具有统计学意义(p<0.05);两组患者治疗持续应答率相近,不良反应发生率相近,相比差异均无统计学意义(p>0.05)。结论:派罗欣联合利巴韦林治疗慢性丙肝的临床效果较为确切,安全可靠,且用法简便,能显著提高患者治疗依从性,从而提高患者治疗效果,值得应用推广。
Objective: To investigate the clinical effect of Pegasys combined with ribavirin in the treatment of chronic hepatitis C Methods: Sixty-two patients with chronic hepatitis C admitted to our hospital from May 2010 to June 2013 were enrolled in this study. Patients were randomly divided into A group and B group. A group of 30 patients were treated with interferon plus ribavirin , 32 patients in group B were treated with Pegasys and ribavirin, and the therapeutic effects and adverse reactions of the two groups were observed. Results: The response rate was 53.3% in group A and 87.5% in group B, and the response rate in group B was significantly higher than that in group A (p <0.05). The response rates of two groups were similar, There was no significant difference in the incidence of adverse reactions (p> 0.05). Conclusion: The clinical effect of Pegasys combined with ribavirin in the treatment of chronic hepatitis C is more accurate, safe and reliable, and its usage is simple and convenient. It can significantly improve patient compliance and improve the therapeutic effect of patients. It is worthy to be popularized.